In addition, other microbiota-targeted manipulation, such as supplementation of TLR antagonists (e.g., polymyxin B), FXR agonists (e.g., obeticholic acid), or prokinetics (e.g., cisapride), also serve as accessary approaches for HCC. The gene discussed is NR1H4; the disease is hepatocellular carcinoma.